Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+TM in seasonal grass pollen rhinoconjunctivitis
NCT01308021Phase 2Completed
- Sponsor
- TOOLS Life Science
- Start
- Dec 2010
- Primary completion
- Oct 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of gpASIT+ in Seasonal Allergic Rhinoconjunctivitis (SAR) (3 arms), sponsored by TOOLS Life Science. Primary endpoint: Impact of gpASIT+TM on the clinical efficacy of the subjects. Started Dec 2010; status: completed.
02
Drugs
gpASIT+
03
Conditions
Seasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT01308021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308021.